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Abstract 
Early diagnosis of cancer is a key strategy for improving cancer outcomes. However, achieving this 
goal can be challenging, particularly for the growing number of people with chronic conditions 
(comorbidity/multi-morbidity). This is because pre-existing diseases may impact patient participation 
in cancer screening, help-seeking for new/changing symptoms and clinicians’ decision-making on use 
of diagnostic investigations. Evidence suggests that pre-existing pulmonary, cardiac, neurological and 
psychiatric conditions are associated with longer patient and diagnostic intervals and advanced stage 
at diagnosis. In contrast, hypertension and some gastrointestinal and musculoskeletal conditions may 
be associated with prompt help-seeking and timely cancer diagnosis. We propose a comprehensive 
framework that encompasses how disease, patient and healthcare factors may influence the 
diagnostic process in cancer patients with pre-existing chronic illness. Previously postulated 
aetiological mechanisms (including the ‘alternative explanations’, ‘competing demands’ and 
‘surveillance effect’ hypotheses) are integrated with newly identified mechanisms, such as false 
reassurance by investigations performed for chronic disease monitoring, or patient worry of 
appearing hypochondriac. By considering the specific effects of chronic diseases on the diagnostic 
process and its outcomes, tailored early diagnosis initiatives can be developed to improve health 
outcomes for the large proportion of cancer patients with pre-existing chronic conditions.  
 
 
Key messages 
• Many individuals with possible cancer symptoms have pre-existing chronic diseases 
(comorbidity, multi-morbidity), which can impact diagnostic timeliness and cancer stage at 
diagnosis.  
• There is evidence that pulmonary, cardiac, neurological and psychiatric disorders are 
associated with longer intervals before cancer diagnosis and more advanced stage at 
diagnosis. 
• Effects seem to vary in direction and size according to pre-existing disease type and the 
nature of presenting symptoms. 
• Targeted interventions to expedite cancer diagnosis and improve cancer outcomes may be 
possible by considering the effects of chronic diseases on participation in cancer screening, 
patient help-seeking for cancer symptoms, and doctor’s decision-making about the use of 
investigations. 
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Early diagnosis of cancer is a key strategy for cancer control1 and for improving cancer outcomes. 
However, many cancer cases arise in patients with pre-existing chronic conditions, and how to 
achieve early diagnosis among this growing patient group remains unclear. Approximately three out 
of four cancer patients have at least one pre-existing chronic disease2 3. The relationship between 
cancer and other chronic conditions has different dimensions4,5: i) Many conditions share common 
risk factors with cancer; for example, chronic obstructive pulmonary disease (COPD) and lung cancer 
are both associated with tobacco smoking; similarly, high alcohol intake and obesity increase the risk 
of both cancer and non-neoplastic chronic conditions. ii) Chronic conditions can influence the risk of 
developing cancer and cancer prognosis through specific biological mechanisms; for example, 
diabetes increases the risk of developing colorectal, breast, endometrial, pancreatic and other 
cancers through a complex biological pathways related to insulin-like growth factors, insulin 
resistance, compensatory increased insulin levels and prolonged hyperglycemia6-8; similarly, some 
chronic infections (such as hepatitis C) and conditions characterized by dysregulation of the immune 
systems can also increase the risk of developing cancer through specific biological mechanisms. iii) 
Certain treatments for chronic diseases can influence cancer incidence and aggressiveness; for 
example, nonsteroidal and anti-inflammatory drugs used for arthritis9, aspirin for cardiovascular 
disease10 or metformin for diabetes might reduce the risk of cancer in some patients6 11. iv) Lastly, 
chronic conditions can affect the timeliness of cancer diagnosis by influencing the diagnostic 
process12-14. In this review we focus on the latter aspect of the association between chronic diseases 
and cancer. 
In particular, we herein examine the influence of chronic conditions on the diagnostic process and 
their impact on two prognostically important diagnostic outcomes: stage at diagnosis, and 
emergency presentation status. Motivated by the limitations in current evidence15-18, we also 
consider whether the impact varies for specific chronic diseases and cancer types. To elucidate 
mechanisms through which chronic diseases may influence the diagnosis of cancer, we review the 
evidence on disease-specific effects on various process measures that characterise the diagnostic 
pathway: participation in cancer screening; patients’ help-seeking for cancer symptoms; clinicians’ 
decision-making regarding use of investigations; and time from symptom onset to diagnosis.  
By considering previously described and newly identified mechanisms arising from the reviewed 
quantitative and qualitative literature, we propose a comprehensive framework, which can guide the 
development of targeted interventions for expediting cancer diagnosis. This is important for 
improving cancer outcomes given the increasing number of individuals with pre-existing conditions1 
19.  
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Variability of measures for defining chronic diseases  
In Box 1 we have provided definitions of commonly used terms. There is considerable variability in 
terminology and methods used to measure morbidity. Studies often rely on coded patient record 
entries for episodes of care preceding the diagnosis of cancer. Composite comorbidity measures such 
as the Charlson Comorbidity Index are used frequently, without detail on specific morbidities.  
The Charlson Comorbidity Index, which was originally developed to predict 1-year mortality in 
hospitalized patients, assigns weights to different chronic conditions providing a summary 
comorbidity score. The weights are based on the ratio of the mortality risk for patients with the 
condition of interest versus the risk for patients without that condition20,21. Disease severity and 
duration and some diseases, such as psychiatric conditions, that might be particularly relevant for 
timely cancer diagnosis, are not taken into account when calculating either the Carlson index or 
similar summary measures. Overall, there is no gold-standard for measuring comorbidity in the 
context of cancer5 and little is known on the performance of summary comorbidity measures when 
evaluating diagnostic timeliness.  
At the same time, many studies include information on specific chronic diseases (as opposed to 
composite measures), identified through case note reviews and patient or healthcare provider 
reports (Figure 1 and Supplementary Table 1).  
Most evidence refers to patients who have been diagnosed with a few common cancers (colorectal, 
lung, breast); some research refers to symptomatic individuals not yet diagnosed with cancer 
(Supplementary Table 1).  
The review includes original research based on quantitative, qualitative and mixed methods. 
Qualitative studies are included to acquire insights into the complex effects of chronic conditions and 
underlying mechanisms. The available evidence refers to cohort (n=31), cross-sectional (n=25) and 
case-control (n=6) studies, as well as case-series (n=13) and qualitative studies (n=11). A quality score 
was assigned to each reference according to the Mixed Methods Appraisal Tool (MMAT)22 (further 
details on the review methods are provided in the Supplementary Box and Figure). The MMAT is a 
validated quality assessment tool, allowing to evaluate each study based on various criteria specific 
for the different study designs (highest possible score 100, if all criteria are met). Most studies 
received a MMAT score of 75 or 50 (35 and 31 studies, respectively); a score of 100 was given to 11 
studies; only 1 study was scored 25. Details on MMAT score, study design and sample characteristics 
are provided in the Supplementary table.  
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Box 1: Key Terminology  
 
Diagnostic pathway: sequence of events and related actions leading to cancer diagnosis. It includes 
events taking place from the onset of possible cancer symptoms or first cancer-related investigation 
(including screening tests) up to when the cancer is diagnosed. Given the variability of prior 
definitions23 this definition considers the Model of Pathways to Treatment12,14, the Routes to 
Diagnosis24 and NICE pathways guidance25. 
 
Multimorbidity: co-existence of several conditions (two or more) in an individual. Both non-
communicable diseases (including history of cancer and non-neoplastic diseases) and chronic 
infectious diseases (HIV, hepatitis C) are encompassed. Definition in line with recommendations from 
the UK Academy of Medical Sciences19. 
 
Comorbidity or chronic diseases in the context of cancer: one or more chronic conditions in a 
patient with cancer or under investigation for a possible cancer. Definitions and time-windows pre-
cancer vary21 (for example, 5 years or 3 months pre-cancer; or at hospital admission when cancer is 
diagnosed). Measures include aggregate comorbidity scores based on secondary care records (for 
example, Charlson Comorbidity Index), specific comorbidities identified through case note reviews of 
primary or secondary care records or patient-reports.  
Diagnostic time or diagnostic interval: time from first symptomatic presentation in primary care to 
the cancer diagnosis. Definition in line with the Aarhus statement26. Some studies only report 
‘diagnostic delay’ with various definitions (for example, >3 months or >6 months). The term diagnostic 
interval is preferable to ‘delay’, as the latter relies on subjective judgement which may have poor 
reproducibility14.    
Patient or help-seeking interval: time from when a patient first notices a symptom to the first 
medical visit for that symptom. It can relate to actual experience or intended help-seeking behaviour. 
Definition in line with the Aarhus statement26. Some studies only report ‘patient delay’ with various 
definitions (>3 weeks, >3 months or median time longer compared to a reference group). Evaluating 
the patient interval rather than ‘delay’ is preferable to avoid subjective judgements14.  
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IMPACT ON DIAGNOSTIC OUTCOMES  
Cancer stage at diagnosis 
The evidence on the effects of chronic diseases on cancer stage is mixed, with some studies 
indicating an association with advanced stage27-41, others showing no effect42-44 and some reporting a 
reduced risk of advanced stage27,30,33,36,39,40,44-46 for patients with chronic diseases (Figure 1).  
An increased risk of advanced stage was found for most of the 42 examined chronic diseases 
examined in a large New Zealand study of 14,096 patients with different cancers27. The risk was 
particularly high for dementia, neurological, pulmonary, cardiac and major psychiatric disorders, with 
odds ratios (OR) ranging between 1.27 and 6.26. Psychiatric conditions were also associated with 
more advanced cancer stage in other studies30,31 (e.g. advanced breast cancer: OR=1.27, p<0.0130; 
advanced oesophageal cancer occurring in 37% versus 18% (p=0.009) of patients with and without 
psychiatric illness31). Moreover, according to large US studies41,47 individuals with psychiatric 
conditions and with dementia are also more likely to be diagnosed with colon cancer at an unknown 
stage (for example, dementia versus non-dementia individuals: 24% versus 7.4%, p<0.001; adjusted 
OR=2.12; 95%CI 1.77-2.55) and using non-invasive methods (imaging, laboratory tests without 
histological confirmation) rather than with tissue evaluation (dementia versus non-dementia 
individuals: adjusted OR=2.02; 95%CI 1.63-2.51)47. 
As reported by a US study including 11,312 patients, those with alcohol and tobacco-related chronic 
conditions have a higher risk of advanced stage head and neck cancers compared to non-comorbid 
patients (39% versus 6%; p<0.05), irrespective of consultation frequency38. The risk of advanced stage 
was also increased by severe renal disease, substance abuse and vascular conditions among prostate 
cancer patients36, and by diabetes, haematological and psychiatric morbidities among breast cancer 
patients30 (ORs between 1.15 and 2.06) in two large US studies. According to another US population-
based cohort study40, end stage renal disease (ESRD) patients on dialysis have a higher likelihood of 
non-localized prostate cancer at diagnosis compared to non-ESRD individuals (13.7% versus 6.5%; 
adjusted RR=2.23; 95%CI 1.35-4.13, controlling for socio-demographic factors and comorbidity 
index); in contrast, they have a lower likelihood of advanced colorectal cancer (39.0% versus 50.9%; 
adjusted RR=0.81; 95%CI 0.66-0.98).  
A lower likelihood of advanced cancer stage was also reported for individuals with hypertension, 
dyslipidemia and coronary artery disease in a large US study on prostate cancer patients (ORs 
between 0.67 and 0.84)36 and for individuals with benign breast, gastrointestinal, musculoskeletal 
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and cardiovascular conditions in another large US study on breast cancer patients (ORs between 0.62 
and 0.87)30.  
One small study  (including 72 women), reported different effects by type of psychiatric morbidity: 
major depression increased the risk of advanced breast cancer, while phobia decreased the risk35. 
Information on consultation frequency was not available.  Heterogeneous effects have also been 
reported for diabetes, depending on its severity32: poorly controlled diabetes was associated with 
advanced colorectal cancer (OR=2.1; 95%CI 1 to 4.4; p=0.02), while this was not the case for well-
controlled diabetes. Disease-specific effects might also be modified by patient factors (for example, 
age), healthcare factors and tumour characteristics (symptom ‘signature’ of the cancer), but the 
evidence on possible effect modification is scant.  
In summary, the evidence suggests that the presence of chronic diseases is associated with cancer 
stage at diagnosis, but effects vary by condition. Some diseases, such as dementia, neurological, 
pulmonary, cardiac and major psychiatric disorders are associated with an increased risk of advance 
stage at diagnosis across cancer types. In contrast, hypertension, dyslipidemia, benign 
gastrointestinal and musculoskeletal conditions, are associated with a lower risk of advanced stage, 
across cancers. Heterogeneous effects on advanced cancer stage were reported for end stage renal 
disease, increasing the risk for prostate cancer and decreasing it for colorectal cancer. 
 
Diagnosis of cancer as an emergency  
Across various countries, a substantial minority of cancer patients are diagnosed in an emergency 
context17. Efforts to prevent emergency presentations are justified because such diagnoses are 
associated with worse clinical outcomes and patient experience24,48,49. The majority of evidence 
suggests that patients affected by chronic conditions have a higher risk of diagnosis of cancer as an 
emergency39,48,50-62 (Figure 1). An English study on emergency diagnosis of any cancer reported a 1.3 
risk ratio (95%CI 1.1-1.7) for patients with any comorbidity compared with those without (i.e. 
Charlson comorbidity score of 1 versus 0)60. Similarly, compared with patients without any 
comorbidity, the risk of emergency colorectal cancer diagnosis was higher for patients with one 
comorbidity (OR=1.5; 95%CI 1.4-1.6) and even higher for 3+ comorbidities (OR=2.0; 95%CI 1.8–2.2)48. 
This concords with a US study showing higher risks of emergency presentations for colorectal and 
lung cancer (OR=1.89; 95%CI 1.7-2.2 and OR=3.79; 95%CI 3.1-4.6, respectively) among patients with 
one versus no chronic disease39.  
Only a few studies examined the effect of specific conditions on emergency cancer diagnoses54,62-66, 
9 
 
and some conditions appear to be associated with particularly high risks, including dementia, cardiac 
and neurological diseases54 (dementia OR=2.46; 95%CI 2.2-2.8; congestive heart failure OR=1.49; 
95%CI 1.4-1.6). Among women younger than 60 years of age, benign gynaecological and new onset 
gastrointestinal conditions were associated with particularly higher risks of emergency colon cancer 
diagnosis (adjusted OR=3.41; 95%CI 1.17-9.93 and 2.84; 95%CI 1.04-7.70, respectively, after 
accounting for symptomatic presentation, other comorbidities and socio-demographic factors)62. 
Obesity has also been associated with emergency presentations65.  
In contrast, a Swedish study described a possible ‘protective’ effect of certain conditions, as it found a 
higher prevalence of hypertension among non-emergency colon cancer patients compared to those 
diagnosed as an emergency64. Likewise, hypertension monitoring in primary care was also associated 
with a lower likelihood of emergency colon cancer diagnosis in a longitudinal UK population-based 
study, taking symptoms, various comorbidities and socio-demographic factors into account (for 
example, among 70-79 year old women adjusted OR=0.62; 95%CI 0.43-0.92,)62.  
In summary, similar to the impact on cancer stage, some conditions, such as dementia, neurological 
and cardiac conditions are associated with an increased risk of emergency diagnosis. In contrast, 
hypertension can be associated with a lower risk of emergency cancer diagnosis. This is also in line 
with previously mentioned studies reporting a lower risk of advanced cancer stage at diagnosis for 
hypertensive patients. Hypertension is a risk factor associated with cardiovascular diseases, rather 
than a chronic disease per se. However, it is worth considering that its management, which can 
involve frequent healthcare contacts, can influence diagnostic timeliness. 
 
 
 
IMPACT ON THE DIAGNOSTIC PROCESS 
Herein, we examine the evidence on disease-specific effects on various process measures 
characterising the diagnostic pathway.  
Participation in cancer screening  
Participation in breast cancer screening is higher in women with one chronic condition compared to 
those with none (adjusted OR 1.31; 95%CI 1.17-1.46, controlling for age, education, country of birth 
and other socio-demographic factors) or two or more conditions (adjusted OR=1.2; 95%CI 1.05-1.32), 
according to a large Canadian population-based cohort study67. However, after accounting for 
disability, which is often associated with chronic conditions, women with severe disability are less 
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likely to participate in breast screening compared with those with moderate (adjusted OR=0.72; 
95%CI 0.63–0.82) or no disability (adjusted OR=0.88; 95%CI 0.78–0.99)67. The highest screening 
proportion (75%) was observed among women with one chronic condition and moderate disability, 
with the lowest referring to women with two or more conditions and severe disability (61%)67. 
Similarly, a large Canadian study using linked data reported that women with a no chronic condition 
and no disability had the highest proportion of cervical cancer screening (64.5%), while the lowest 
proportion was observed among women with two or more morbidities and severe disability 
(39.8%)68. Studies in the US have also reported how increasing Charlson comorbidity scores are 
associated with a lower probability of breast and cervical screening, possibly because physicians are 
less prone to recommend screening in patients with worse overall health status and/or patients 
refusing screening69. Further, according to a large population-based cohort study in the US, 
participation in colorectal cancer screening decreases with increasing levels of comorbidity (88% of 
65-69 year old individuals underwent screening if their Charlson score was 0 versus 82% if their score 
was >4, p<0.001)70. 
Considering specific chronic conditions, two large US population-based surveys have shown that 
women aged 40 years or older with diabetes are more likely than those without to be screened for 
colorectal cancer71,72; specifically, screening prevalence was 63% versus 60% (p<0.05) among diabetic 
versus non-diabetic women, adjusted OR=1.14; 95%CI 1.04-1.24, accounting for socio-demographic 
factors, health insurance, body mass index and smoking71. The opposite effect was reported by a 
different US population-based survey among older women (≥67 years) (adjusted OR=0.79; 95%CI 
0.70-0.88)73. These American studies were limited to women only, but an English prospective survey 
of 55-year old men and women has shown a lower probability of flexible sigmoidoscopy screening for 
individuals with diabetes compared to those without (adjusted OR=0.48; 95%CI 0.25-0.94)74.  
Women with diabetes were also less likely to participate in breast cancer screening compared to non-
diabetic women in two large Canadian studies75,76 (60% versus 66%; OR=0.79, 95%CI 0.78-0.80, after 
adjustment for socio-economic status and overall comorbidity)75. Similarly, two other Canadian 
studies, found a lower participation in breast cancer screening in women with HIV infection (50% 
versus 63%)77 or depression (46% versus 62%; adjusted OR=0.63; 95%CI 0.40-0.97)78, while evidence 
from Spain indicates that this was also the case in obese women (64% versus 69%)79. Two US studies 
have also reported how obesity is associated with a lower participation in breast80 and cervical81 
screening, after adjustment for socio-demographic factors, health care access, general health status, 
other comorbidities and health-seeking behaviour. 
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In contrast, musculoskeletal conditions are associated with a higher probability of breast screening in 
a Spanish study (75% versus 63% in women with and without musculoskeletal conditions; adjusted 
OR=1.46; 95%CI 1.22-1.77)79.  
In summary, individuals with multiple chronic disease are less likely to participate in breast, cervical 
and colorectal cancer screening, especially if there is associated disability. Regarding specific 
conditions, HIV infection, depression and obesity are associated with a lower probability of cancer 
screening. In contrast, musculoskeletal conditions are associated with a higher probability. 
Heterogeneous effects have been reported for individuals with diabetes. 
 
Help-seeking for possible cancer symptoms  
Chronic diseases can influence help-seeking behavior in the context of new or changing symptoms. 
They can have variable effects63,82-86, with some diseases being associated with shorter87 and others 
with longer patient intervals88-92, while some studies93-95 found no such effects (Figure 1).  
A study of patients with lung cancer91 showed that those with COPD took twice as long to consult 
with lung cancer symptoms (mean help-seeking interval 166 versus 81 days), while those with a 
history of renal failure had significantly shorter patient intervals than non-comorbid patients (mean 
of 53 versus 102 days, respectively). A survey on help-seeking for various cancer symptoms90 
highlighted how pre-existing cardiac conditions were associated with a lower likelihood of help-
seeking for change in bowel habit (OR=0.4; 95%CI 0.2-1.0); in contrast, hypertension increased help-
seeking for persistent cough (OR=2.0; 95%CI 1.1-3.5) or abdominal bloating (OR=2.3; 95%CI 1.1-4.8) 
and chronic urinary diseases increasing help-seeking for rectal bleeding (OR=5.8; 95%CI 1.4-23.8). A 
small Japanese study on 134 cancer patients reported how individuals with dementia had sought help 
less frequently for cancer symptoms compared to individuals without dementia (8% versus 63%, 
p<0.001)96.   
In summary, the evidence on the effects of chronic diseases on help-seeking is heterogeneous, 
depending on the chronic condition and cancer site. While some studies showed no association, 
others reported longer patient intervals, for example when chronic conditions and cancer have 
overlapping symptomatology (COPD and lung cancer) or when ‘serious’ diseases (cardiac conditions) 
are present; in contrast, hypertension is associated with help-seeking for potential cancer symptoms.      
 
Diagnostic events post-presentation  
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Beyond their effect on patient help-seeking, chronic diseases can also influence healthcare providers’ 
decision-making (sometimes in combination with patient factors) regarding diagnostic reasoning and 
referrals for specialist investigations or use of diagnostic tests.  
Diagnostic process, referrals and use of investigations. Some studies58,94,97-99 only examined the 
overall effect of any disease (rather than specific diseases) on the diagnostic process (Figure 1). 
Having any chronic disease versus none had no effect on specialist referrals for gynaecological 
cancers94 or on gastroscopy rates among oesophago-gastric cancer patients58.  
On the other hand evidence on the effects of specific chronic diseases is provided by several 
studies2,40,57,82,85,86,88,89,95,99-102. In particular, congestive heart failure or coronary artery disease can 
lead to missed opportunities to refer patients promptly for endoscopic examination101, despite 
symptoms of colorectal cancer. Psychiatric illness was also associated with prolonged pre-referral 
intervals to a specialist or colonoscopy (with referral occurring after 60 days or more) in a study on 
colorectal cancer (adjusted OR=4.0; 95%CI 1.1-13.9)85. End stage renal disease can have 
heterogeneous effects according to a US cohort study, increasing the likelihood of 
colonoscopy/flexible sigmoidoscopy (OR=3.65; 95%CI 1.21-11.03) and decreasing the likelihood of 
PSA testing (OR=0.59; 95%CI 1.21-11.03)40. 
 
Diagnostic interval (from first presentation to diagnosis). Some studies examined disease-specific 
effects on the diagnostic interval31,57,82,83,85,86,88,95,100,103,104; others only examined the overall effect of 
any chronic disease84,94,98,99,102,105-110 (Figure 1). Overall, having any pre-existing disease is strongly 
associated with a longer diagnostic intervals, according to two large studies on leukemia and 
myeloma108,109 and one on lymphoma98. For example, chronic lymphocytic leukemia patients with a 
pre-existing condition (versus none) had OR=2.83 (95%CI 2.5-3.3) for a prolonged diagnostic interval 
(defined as longer than the average time of 63 days between first symptomatic presentation and 
diagnosis)109. A longer diagnostic interval was also reported among upper aero-digestive tract cancer 
patients with a pre-existing disease versus none (OR=2.84; 95%CI 1.35-5.98)105 and for oral cancers 
(42% of individuals with sever comorbidity level had a diagnostic interval >1 year, compared to 7% 
among individuals with modest or no comorbidity, p=0.002) 84. Among laryngeal cancer patients105, 
42% experienced a diagnostic interval of more than one year if Charlson comorbidity score>3, 
compared to 7% if comorbidity score 0-2. 
A UK cohort study on colorectal cancer based on electronic primary care records103 showed that 
specific diseases are associated with longer intervals before the cancer diagnosis: inflammatory 
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bowel disease was the condition most strongly associated with an increase in the diagnostic interval 
(a median increase of 26 days [14 to 39]; and a geometric mean value 1.33-fold greater [95%CI 1.18-
1.51] in patients with inflammatory bowel disease, controlling for age and gender); other conditions 
associated with significantly longer diagnostic intervals were coronary heart disease (15 days [7 to 
24]), anxiety/depression (9 days [3 to 17]) and diverticular disease (14 days [3 to 27]). Effects of pre-
existing diseases were stronger among individuals aged 80 or more. Similarly, mental health 
problems and gastro-intestinal conditions were associated with longer diagnostic intervals in a large 
study on colorectal cancer95. Psychiatric illness was also associated with a longer diagnostic interval 
for oesophageal cancer (median 90 days in comorbid versus 35 days in non-comorbid patients, 
p<0.001)31.  
 
Performance of investigations. The evidence on the effects of chronic diseases on performance of 
investigations is scant. No difference in false-positive rates by Charlson comorbidity score111 has been 
reported in older women undergoing breast cancer screening. A higher risk of colorectal cancers after 
a previous negative colonoscopy has been reported for patients with chronic diseases (OR=1.16; 
95%CI 1.1-1.3)97. Such occurrences are thought to primarily reflect missed lesions or incomplete 
polypectomy at the index colonoscopy112. Pre-existing diseases might lead to difficulties with bowel 
preparation113 and/or increased technical difficulties for the endoscopist114,115 or reduced patient 
tolerance during the examination, interfering with the endoscopic examination and possibly 
increasing the risk of missed lesions.  
In summary, the evidence on the effects of chronic conditions on the diagnostic process indicates 
that they are associated with a lower likelihood of prompt specialist referral and lower use of 
specialist investigation (such as colonoscopy) and with prolonged diagnostic intervals. For some 
conditions, including cardiac and psychiatric conditions, such findings have been reported across 
cancer types; for other conditions (inflammatory bowel disease or diverticular disease) this applies to 
specific cancers presenting with similar symptomatology (colorectal cancer). Differently from other 
conditions, end stage renal disease can be associated with a higher likelihood of colonoscopy/flexible 
sigmoidoscopy. 
 
MECHANISMS OF INFLUENCE  
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While quantitative research has allowed to document associations with diagnostic outcomes, thus 
far, there is a lack of quantitative studies specifically designed to evaluate the mechanisms by which 
chronic diseases might influence the cancer diagnosis (Box 2). Currently, details on possible 
mechanisms are mostly provided by qualitative research (Supplementary Tables 2-3). 
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Box 2: Mechanisms by which chronic diseases might influence the cancer diagnosis Examples of pairs of chronic 
disease/treatment and cancer
MECHANISMS INTERFERING WITH TIMELY CANCER DIAGNOSIS 
Pre-existing theories  
• Alternative explanation: Cancer symptoms are attributed by patients and/or doctors to a pre-
existing condition or its treatment. Particularly relevant when symptoms of cancer and of the 
chronic condition overlap.18,30,36,103 
COPD and lung cancer82,91; 
IBD/IBS/diverticular disease and 
colon or ovarian cancer86,103; 
Beta-blocker or statin-associated 
GI symptoms and CRC88 
• Competing demands: Chronic conditions that are complex to manage or are perceived to be of 
particular gravity can distract the patient and/or doctor from appraising and investigating new 
vague symptoms that might be due to cancer.116 
Cardiac conditions and CRC90,103; 
 
• Pathological hypothesis: Some chronic conditions or their treatments interact with cancer 
pathogenesis, influencing cancer aggressiveness at the cellular or physiological level.30,117 (For  
related effects in the opposite direction see below) 
Diabetes and CRC32,118
Novel theories emerging from the current review  
• Over-reassurance (of patient and/or doctor) from diagnostic tests performed for chronic disease 
monitoring. 
Ultrasound for gynaecological 
condition and colon cancer89  
• Worry/anxiety to be seen as hypochondriac due to frequent consultations for chronic diseases 
or co-exisiting mental health conditions. This might influence patients’ reporting of symptoms. 
Frequent consultations can also influence doctors’ interpretation of symptoms in light of anxiety 
disorders. 86 
Mental health conditions and 
colorectal cancer63,85,86 
• Fatalism (due to morbidity-related poor health) leading to reluctance to undergo investigations or 
cancer screening. 
Multi-morbidity and breast or 
colorectal cancers69,89 
• Communication problems due to specific chronic conditions. 
 
Dementia, mental health, hearing 
problems and GI cancers31,47,96   
MECHANISMS FACILITATING TIMELY CANCER DIAGNOSIS
Pre-existing theories  
• Surveillance effect/Opportunities: Frequent consultations for monitoring or treatment can offer 
patients opportunities to mention possible cancer symptoms or healthcare providers might notice 
new sign/symptoms or they might recommend cancer screening.119   
Hypertension or musculoskeletal 
conditions and CRC62,79,90,92 
Novel theories emerging from the current review  
• Self-efficacy due to familiarity with the healthcare system. This can influence patients and 
indirectly also healthcare providers’ decisions on diagnostic strategies. 
COPD and lung cancer82,92
• Positive expectations due to previous experiences with chronic disease management. Treatment of COPD-associated 
chest infections and lung cancer82 
• Priorities with respect to diagnosing cancer early or facilitating access to health services for 
patients with specific conditions.  
 
COPD ‘management programs’ 
and lung cancer92 
• Pathological hypothesis: Interactions between chronic conditions/treatments and cancer (e.g. 
aspirin) can reduce the risk of metastasis (via effects on platelet functions and other effects). 
Biological interactions can also influence symptoms, for example, end stage renal disease can be 
associated with GI bleeding (due to uremic platelet dysfunction and anticoagulation given during 
dialysis), increasing the likelihood of early cancer diagnosis.40 
Aspirin and CRC10; end stage 
renal disease and CRC40 
 
 
Notes: COPD Chronic Obstructive Pulmonary Disease; IBS Irritable bowel syndrome; IBD Inflammatory bowel disease; CRC Colorectal 
cancer; GI Gastro-intestinal.
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MECHANISMS INTERFERING WITH TIMELY DIAGNOSIS  
Alternative explanation mechanism 
Influencing help-seeking for cancer symptoms. Patients may attribute cancer symptoms to pre-
existing diseases or to treatments for pre-existing diseases88,120 as offering alternative explanations 
for their symptoms. Previous reports most frequently relate to chronic respiratory diseases (COPD 
and asthma) and gastro-intestinal conditions interfering with help-seeking for lung cancer and 
colorectal cancer symptoms, respectively63,82,86,88,91. Supplementary Table 2 illustrates this with 
examples from qualitative studies. 
 
Influencing the diagnostic interval. Chronic diseases can lead to longer diagnostic intervals and 
emergency cancer diagnosis due to missed opportunities57 82  when symptoms are attributed by the 
doctor to a pre-existing disease or its treatments, despite repeated symptomatic presentations63,86. 
Alternative explanations can also be reinforced by doctor-patient interactions83,88 (Supplementary 
Table 3). Interviews with GPs102 indicate that chronic diseases can lead to a longer primary care 
interval in 23% of cancer patients, most frequently because of alternative explanations: in 90% of 
comorbid lung cancer patients with longer primary care intervals, symptoms were ascribed to a pre-
existing disease. In a study on colorectal cancer103 chronic conditions classified as representing 
'alternative explanations' increased the diagnostic interval (by an average of 9 days; inflammatory 
bowel disease was associated with the largest increase, i.e. average 26 days). Reviews of GP free text 
notes86 and significant event audits57 highlighted missed diagnostic opportunities in patients with a 
history of diverticulitis or gynaecological conditions, with both GPs and specialists initially attributing 
colorectal or ovarian cancer symptoms to these conditions or related medications.  
 
Competing demands mechanism  
Influencing help-seeking for cancer symptoms. Some chronic diseases may lead to a prolonged 
patient interval if they are perceived to be of particular gravity (e.g. heart disease), diverting 
attention from new symptoms, especially if vague. For example, a survey90 highlighted how having a 
cardiac condition decreased the likelihood of prompt help-seeking for change in bowel habit. 
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Influencing the diagnostic interval. Doctors can prioritise the treatment of pre-existing diseases or 
worry about a patient’s poor health status due to chronic diseases, leading to longer intervals before 
investigations involving invasive procedures89. For example patients with congestive heart failure or 
coronary artery disease, might not be referred promptly for endoscopic investigation of possible 
colorectal cancer symptoms101. Another study103 showed that a single ‘competing demand’ condition 
(for example, coronary heart disease) increased the diagnostic interval for colorectal cancer by 10 
days, and four or more conditions by 32 days in the average patient. 
 
Influencing participation in cancer screening. Competing demands may also influence participation 
in cancer screening, as suggested by the lower probability of appropriate screening in individuals with 
diabetes, HIV infection or depression. Multi-morbid patients with complex needs and their healthcare 
providers have to deal with competing demands and fragmentation of care involving multiple 
specialist services, possibly  interfering with access to preventive services75,76 77 78. 
Overall, the competing demands mechanisms can explain, at least partly, the higher risk of advanced 
cancer stage among patients with more severe or complex chronic conditions, such as severe 
neurological, pulmonary or cardiac conditions and multi-morbidity. 
 
Pathological/biological mechanisms 
The impact of chronic diseases on timely cancer diagnosis and cancer stage might also be influenced 
by biological mechanisms at tumour level affecting cancer progression. A ‘pathological hypothesis’36 
is supported by some studies6,30,117. For example, chronic conditions such as severe renal diseases 
may be associated with a compromised immune system and metastatic prostate cancer36. Moreover, 
research on diabetes suggests direct and indirect effects of insulin on cancer growth in patients with 
diabetes and/or obesity118,121. Poorly controlled type 2 diabetes is associated with increased risk of 
advanced colorectal cancer32, possibly due to biological effects of chronic hyperinsulinemia and poor 
glycaemic control. Pathophysiological interactions between some chronic diseases (including 
diabetes and chronic renal disease), ageing and cancer progression have been suggested as possible 
explanations for the greater risk of advanced stage in different cancers4,118,121 34. 
Pathological and biological interactions can also have the opposite effect, reducing the risk of 
advanced cancer stage. For example, patients on dialysis for end stage renal disease will likely have 
uremia-related platelet dysfunction and be on regular anticoagulant treatment, increasing the 
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probability of gastrointestinal bleeding. This might explain the higher likelihood of colonoscopy and 
early detection of colorectal cancer in these patients40.  
 
Novel mechanisms  
Some additional mechanisms of influence have emerged from the review (Box 2 and Supplementary 
Tables 2-3), which integrate previously hypothesised theories. The following mechanisms are 
associated with longer patient and diagnostic intervals: 
Patient worries of appearing hypochondriac and repeated consultations. Patients might not seek 
help for possible cancer symptoms, due to worry of being seen as hypochondriac, particularly in the 
context of mental health conditions63. Frequent help-seeking of patients can also influence the 
doctor’s interpretation of symptoms in light of anxiety disorders. According to a study on colorectal 
cancer86, patients with higher consultation rates for a variety of complaints were referred less for 
investigations, possibly because healthcare providers sometimes perceive frequent help-seekers as 
being over-vigilant about body changes.  
Sometimes multiple visits can be due to complex diagnostic processes100: investigations can lead to 
the diagnosis of previously undetected morbidities, distracting healthcare providers from the 
underlying cancer, which is eventually diagnosed after subsequent consultations.  
In some patients, mental health issues can also influence participation in colorectal cancer screening 
when anxiety disorders interfere with enema administration122.  
 
Over-reassurance following investigations performed for a chronic disease. Over-reassurance can 
influence both patients and doctors following diagnostic investigations performed in relation to a 
chronic disease management; moreover, reluctance to refer patients again after a negative test 
(which may however not be specific enough or appropriately targeted to possible cancer) can lead to 
longer time intervals before the cancer diagnosis82 99. GP interviews show also that pre-existing 
conditions can contribute to misinterpretation of tests or to symptoms being attributed to chronic 
diseases when a chest x-ray is negative102.  
  
Fatalism. Poor health status associated with multi-morbidity can lead to patient's reluctance to 
undergo invasive cancer investigations89,92. Similar mechanisms might also contribute to explaining 
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the lower likelihood of patients participating in cancer screening in case of poor health status and 
disability associated with multi-morbidity69. Mental health conditions are also associated with a lower 
likelihood of cancer screening, which might be explained in part by patient's lack of motivation or 
feeling overwhelmed.  
 
Communication problems. Some chronic diseases (dementia, mental health, hearing problems) can 
lead to communication difficulties between patients and healthcare providers leading to longer 
patient and/or diagnostic intervals31. In addition, patients with dementia and mental health 
conditions can also have difficulties with problem-solving behaviour and decision-making possibly 
interfering with timely cancer diagnosis47,96. 
 
MECHANISMS FACILITATING TIMELY DIAGNOSIS 
Surveillance mechanism/opportunities for earlier diagnosis 
Influencing help-seeking for cancer symptoms. In contrast to previously discussed mechanisms 
leading to more advanced cancer at diagnosis, some conditions can be associated with a ‘surveillance 
effect’, which offers opportunities for earlier diagnosis. This is the case when a condition requiring 
regular monitoring can enable the reporting of cancer symptoms during healthcare encounters to 
monitor the chronic condition.  For example, hypertension and chronic urinary diseases can lead to 
more prompt help-seeking for possible cancer symptoms, such as rectal bleeding or cough90. 
Sometimes patients feel that help-seeking for vague symptoms is only appropriate if the consultation 
is ‘justified’ by a co-existing morbidity123, consistent with UK evidence that ‘not wanting to waste the 
GP’s time’ can be a barrier to help-seeking124.  
 
Influencing the diagnostic interval. A chronic disease can also offer healthcare providers 
opportunities to evaluate the possibility of cancer. This can apply to situations when cancer 
signs/symptoms are not mentioned by patients, but are noticed by healthcare providers when 
patients are seen for managing a chronic disease100.  In some cases, the cancer is detected 
incidentally when undergoing investigations for another condition82.  
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Influencing participation in cancer screening. Chronic conditions can also offer opportunities for 
accessing screening, which might explain the increased likelihood of cancer screening in individuals 
with musculoskeletal conditions79.  
Overall, the surveillance mechanism, influencing both patients and healthcare providers, can 
contribute to the protective effect of some conditions, such as hypertension, dyslipidemia or 
musculoskeletal problems, associated with a lower risk of advanced cancer stage.  
 
Novel mechanisms  
The following additional mechanisms of influence associated with shorter patient and diagnostic 
intervals have emerged from the review (Box 2 and Supplementary Tables 2-3): 
Self-efficacy and positive expectations. Familiarity with the healthcare provider due to chronic 
diseases may affect patient's self-efficacy and facilitate help-seeking and communication regarding 
other health concerns92. Moreover, patients with chronic diseases can acquire substantial 
experience, allowing them to identify subtle changes in their symptoms compared to their underlying 
disease, which can trigger help-seeking82. Patients with chronic diseases can also have previous 
positive healthcare experiences motivating them to seek help promptly when they anticipate that a 
prescription can alleviate symptoms82.  
 
Priorities and specialist services for patients with chronic diseases. Specialised care pathways for 
patients with chronic diseases or nurse-led ‘disease management programs’ for some chronic 
diseases (e.g. diabetes, COPD) may facilitate help-seeking for other health concerns92. Moreover, 
guidelines and criteria for accessing diagnostic services targeting patients with specific conditions 
might have a positive impact on cancer diagnosis, by facilitating prompt access to healthcare 
professionals and/or testing for higher risk sub-groups88,92. 
  
IMPROVING CANCER DIAGNOSIS IN COMORBID PATIENTS  
A comprehensive framework  
By integrating the available evidence, we developed a comprehensive framework of the likely 
mechanisms through which chronic diseases can interfere with or facilitate timely cancer diagnosis 
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influencing participation in cancer screening, help-seeking for cancer symptoms, diagnostic strategies 
and use of investigations (Figure 2 and Box 3).  
 
================================================================================== 
Box 3: Framework interpretation (see also Figure 2) 
Chronic diseases can make the diagnosis of cancer less or more timely (red or green arrows in figure 2, respectively). 
These effects may be mediated through various mechanisms (red and green boxes) influencing distinct steps along the 
diagnostic pathway. Chronic diseases and their treatments may also influence cancer progression (top, yellow arrow) 
through pathological interactions (increasing or reducing the risk of rapid progression). Other factors (bottom, yellow 
boxes) including patient, healthcare and tumour factors, can also influence diagnostic timeliness.  
Movements along the pathway are not always linear; some steps may be repeated before diagnosis (blue and orange 
circles and dotted orange arrow), especially if patients initially receive a non-cancer diagnosis (orange box). When 
symptoms persist or evolve, the patient will likely re-appraise symptoms and seek help. Chronic non-cancer diagnoses can 
possibly delay help-seeking through various mechanisms (alternative explanations, competing demands, worry to be seen 
as hypochondriac, fatalism due to poor health status). In contrast, tests or medical consultations performed for a chronic 
disease, might allow earlier diagnosis of cancer (surveillance effect). 
Cancer can sometimes be diagnosed as an emergency (dark red box), for example when repeated consultations did not 
lead to a timely cancer diagnosis (e.g. colorectal cancer progresses to bowel obstruction in patients with diverticular 
disease) due to chronic conditions with overlapping symptoms providing an alternative explanation. 
==================================================================================
22 
 
Novel mechanisms of influence have emerged (Box 2), which integrate previously hypothesised 
theories, including the ‘alternative explanations’, ‘competing demands’, ‘surveillance effect’18,30,36,103 
and ‘pathological hypothesis30,117. Novel mechanisms associated with longer patient and diagnostic 
intervals include false reassurance/over-reassurance (among doctors and patients) following 
investigations performed for a chronic disease; patient worries of appearing hypochondriacal; 
fatalism, due to poor health status associated with multi-morbidity, leading to reluctance to undergo 
invasive cancer investigations. Patients’ overall health status and prognosis, in relation to their 
chronic diseases, can also influence healthcare providers’ decision-making and recommendations to 
their patients regarding screening as well as diagnostic investigations. In contrast, self-efficacy and 
positive expectations (related to their chronic conditions), as well as health services and guidelines 
targeting patients with specific conditions might have a positive impact on cancer diagnosis, by 
facilitating prompt access to healthcare for these higher risk sub-groups.  
It is noteworthy that the identified associations represent ‘average’ effects in population groups. At 
individual level, additional factors (related to the patient or tumour) can come into play. In particular, 
age, socio-economic factors (associated with multi-morbidity)125 and social support might modify the 
effect of chronic diseases on diagnostic processes and outcomes. Moreover, for each patient multiple 
mechanisms may co-occur simultaneously.  
Some chronic conditions, including dementia, neurological, pulmonary, cardiac and psychiatric 
disorders, are associated with a particularly high risk of late cancer diagnosis across cancer types. In 
contrast, hypertension and hypercholestolaemia and some benign musculoskeletal and 
gastrointestinal diseases can be associated with earlier diagnosis.  
Psychiatric illness and dementia are associated with late diagnosis of breast, prostate and gastro-
intestinal cancers. Psychiatric illnesses might provide alternative explanations for cancer symptoms 
which can be misinterpreted (by both patients and doctors) as reflecting the underlying psychiatric 
conditions or medications31. Communication difficulties and worries of appearing hypochondriac may 
also interfere with reporting of cancer symptoms in patients with mental health problems63,89. In 
addition, dementia and other mental disorders can be associated with cognitive impairment and 
difficulties in problem-solving and decision-making, which might interfere with cancer screening, 
adherence to medical recommendations and diagnostic investigations41,47,96. For example, cognitive 
impairment and emotional issues might complicate the informed consent process, discouraging 
healthcare providers from recommending invasive investigations41; patients might also not undergo 
investigations due to difficulties in adhering to specific recommendations (e.g. bowel preparation for 
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colonoscopy)122. The relationship between dementia and cancer is particularly complicated, as some 
studies suggested also a direct biological effect, with patients with Alzheimer’s disease possibly being 
less likely to develop cancer, as well as less likely to be diagnosed with cancer through screening126.  
As mental health conditions are common in the general population31,127,128, interventions to support 
the diagnostic process in these patients are needed. Patients with mental health conditions tend to 
consult frequently but may have difficulties when appraising their symptoms, communicating their 
healthcare needs and navigating the healthcare system. Thus, interventions for their treating 
physicians and supporting access to healthcare services may be particularly justified.  
 
Aggregate comorbidity measures  
While commonly used summary measures, such as the Charlson Comorbidity Index, originally 
developed for predicting mortality, can provide useful information on the overall burden of 
comorbidity experienced by individuals, their use for evaluating the impact of chronic diseases on 
diagnostic timeliness should be carefully considered. All the chronic diseases included in the Charlson 
index are associated with an increased mortality risk (albeit with different weights). In contrast, not 
all chronic conditions increase the risk of advanced disease. Thus, the same weighted sum used on 
the basis of associations with mortality could lead to uninformative results in the context of 
diagnostic timeliness studies, given that some conditions may increase and others decrease the risk 
of advanced cancer at diagnosis. 
While summary measures may offer some advantages in terms of statistical analysis, rather than 
weighting each condition based on their impact on mortality, different weights would be necessary in 
order to adopt the index for evaluating diagnostic timeliness. Weights might also depend on the 
cancer type.  
Moreover, severity and duration of the chronic condition and related treatments are not considered 
in commonly used comorbidity indices, while they can influence diagnostic processes and outcomes. 
In addition, some diseases, such as psychiatric conditions, that can be particularly relevant in the 
context of timely cancer diagnosis, are not included. Overall, existing summary indices, while being a 
useful measure of overall burden of comorbidity, have important limitations and need to be adapted 
and validated before using them for evaluating the effect of chronic diseases on timely cancer 
diagnosis. Considering each chronic condition individually may have important merits, providing 
useful insights and allowing the development of targeted healthcare interventions. 
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Limitations of the current evidence 
Definitions of chronic diseases and data collection methods vary substantially across studies and this 
might have contributed to the variability of findings. Effects of chronic diseases might be influenced 
by their severity and duration, but such information is rarely reported. Some studies suggested that 
competing demands mechanisms might affect particularly older patients, but evidence on effect 
modification by socio-demographic characteristics is scant. As the majority of studies are based on 
retrospective reports by cancer patients, recall bias might have influenced the findings129. More than 
half of included studies did not specifically aim to investigate the effects of chronic diseases, and 
relevant information often emerged only after in-depth examination of full-text publications. 
Publication bias might have limited the number of studies showing no impact.  Most studies report 
prevalence odds ratios, which might provide a biased estimate of the prevalence rate ratio if the rare 
disease assumption is not met (when the outcome of interest is fairly common). Absolute estimates 
and their difference are particularly useful from a clinical point of view, but studies do not 
consistently report them. 
 
Implications for policy and practice 
The reviewed evidence and the proposed theoretical framework can inform the development of 
targeted strategies aimed at improving early cancer diagnosis for people with pre-existing conditions 
(Exemplified in Box 4).  
 
Box 4: How the framework can help develop strategies for improving timely cancer diagnosis  
The proposed framework can be used by healthcare providers, policy-makers and researchers for identifying targets and 
possible actions for improving timely cancer diagnosis for patients with chronic conditions and to identify relevant 
processes leading to more advanced cancer. Disentangling the mechanisms will allow the development of possible 
interventions. For example, individuals with mental health conditions are less likely to participate in cancer screening and 
can delay help-seeking for possible cancer symptoms. They are also less likely to be promptly referred if they develop 
cancer symptoms. This suggests that interventions are needed in both the pre-symptomatic and symptomatic stages. 
Moreover, identifying specific mechanisms involved can suggest possible targets for interventions. For example, 
individuals with mental health conditions might be more likely to worry about being perceived as hypochondriac and be 
more prone to fatalism because of poor health status (due to multi-morbidity), with an increased risk of delays in help-
seeking for symptoms. They might also worry about investigations and how to navigate the healthcare system, interfering 
with screening and diagnostic testing. Such information can inform the development of appropriate support for these 
vulnerable patients. 
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The primary care interval can also be influenced by similar mechanisms. Doctors might dismiss possible cancer symptoms, 
interpreting them in light of anxiety disorders in patients with mental health conditions who consult frequently 
(‘hypochondriac effect’); patients' poor health status might also affect doctors' propensity to refer them for invasive 
investigations. Clinical decision-support tools and healthcare models promoting greater care integration might be needed 
here.  
The framework can also highlight areas and mechanisms where chronic diseases could offer opportunities for earlier 
diagnosis. For example, through the surveillance effect, whereby frequent encounters with healthcare providers can offer 
opportunities for diagnosing cancer earlier, could be used in the case of patients with mental health conditions. Novel 
technologies allowing less invasive and simpler cancer tests, for example quantitative FIT, could be particularly useful for 
patients whose clinical condition may make it difficult to tolerate a colonoscopy.   
Finally, the framework can be used by researchers to identify areas where evidence is lacking and further studies are 
needed. 
==================================================================================
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The global burden of chronic diseases and multimorbidity has increased over the last decades130, due 
to lifestyle factors and improved life expectancy131-135, with more than half of the population aged 60 
years or older in high income countries having a chronic condition and a quarter having 
multimorbidity132,136,137. Further, one in four deaths before the age of 60 are due to chronic 
conditions19 130. This underscores the importance of improving cancer diagnosis and management in 
the context of chronic diseases19,125,138,139.  
According to the Social Cognitive Theory140 a person's decision to seek help can be influenced by 
various factors, including their perceived ability to discuss a symptom and receive help (‘self-
efficacy’), socio-cultural and structural barriers, opportunities and ‘outcome expectations’. Self-
efficacy is affected by previous experiences and it can influence both patient help-seeking and doctor 
decision-making. In that context, chronic diseases present both ‘opportunities’ to discuss cancer 
symptoms123, but also ‘barriers’ if the patient and/or doctor perceive the pre-existing condition as 
more important18 141. Developing guidelines that take multi-morbidity into account and improving 
access to appropriate diagnostic services can have positive effects on timely cancer diagnosis. 
Conceptual models of diagnostic safety13,17,142,143 can help identifying specific areas for improvement; 
they highlight how system and cognitive factors can contribute to prolonging the time before cancer 
diagnosis, with missed opportunities potentially occurring during the different phases of the 
diagnostic process (initial assessment; diagnostic test performance and interpretation; follow-up and 
coordination)13. This is in line with the findings of the current review, highlighting how various steps 
along the diagnostic pathway can be influenced by the presence of chronic diseases, calling for multi-
faceted interventions.  
When patients present with multiple conditions, it is often necessary to prioritise how much time is 
dedicated to the optimal management of serious pre-existing diseases against investigating new and 
possibly vague symptoms, particularly in the context of limited consultation time. Allowing sufficient 
time during primary care encounters remains paramount. Information technology144 and electronic 
health records could be used by primary care providers to identify complex patients, allowing to plan 
allocation of time and optimizing the provision of care, for example by involving specialist nurses 
before and/or after a visit dedicated to multi-morbid patients. Similar approaches have been 
suggested in a recent project for the management of multi-morbidity145.  Patients that are at 
increased risk could benefit from information technology-enabled monitoring systems. There is also 
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scope for enhancing the surveillance effect, by explicitly building in a cancer symptom enquiry to 
routine surveillance of chronic diseases. 
Multi-disciplinary diagnostic centres (recently introduced in Denmark and England146-149) for patients 
with serious but non-specific symptoms could also be useful in the case of diagnostic complexities 
due to pre-existing chronic diseases. Although such centres have not been specifically developed for 
patients with pre-existing conditions, ongoing evaluations of their effectiveness in achieving timely 
cancer diagnosis in complex patients could generate relevant evidence in the near future149,150.  
Greater integration between primary and secondary care, as well as wider use of ‘disease 
management programs’ coordinated by specialist nurses (for example, for patients with diabetes or 
mental health problems), could allow patients to have easier access to healthcare providers.  
More effort should be dedicated to raising both patient and healthcare provider awareness on the 
benefits of cancer screening in patients with multi-morbidity. It also remains important to ensure 
that screening recommendations take the severity of chronic conditions and the presence of life-
limiting conditions into account, evaluating benefits and risks151. Information material specifically 
targeted at higher risk groups, addressing possible difficulties or concerns might be useful. 
Integration of the management of chronic conditions and cancer screening protocols would seem 
justified.  Primary care-based preventive programmes, based on patients’ age and risk profiles might 
be more acceptable for patients and more cost-effective152,153. 
Care coordination, including follow-up after investigations and safety-netting are crucial for multi-
morbid patients, considering the risk of false reassurance after investigations for a chronic disease 
possibly leading to later cancer diagnosis. By sharing the diagnostic plan with patients and clearly 
communicating when there is uncertainty, patients might feel more empowered to raise concerns. 
Moreover, giving patients easy and timely access to their medical records and inviting them to pro-
actively follow-up test results might contribute to preventing diagnostic delays100,154. 
 
Research priorities 
Further research is warranted on the impact of chronic diseases on clinicians’ decision-making 
regarding diagnostic strategies and use of investigations. The limited available information is only 
indirectly provided by a few interview studies and significant event audits. Studies examining 
cognitive processes, including vignette studies, may be particularly useful155-158.  
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There is limited evidence on specific symptom-morbidity pairs57,63,82,100: for example, breathlessness 
in patients with chronic lung or cardiac morbidities leading to longer diagnostic intervals in lung 
cancer. Large studies based on linked electronic health records and trials evaluating different 
diagnostic strategies for patients with specific morbidity-symptom pairs could help identify optimal 
diagnostic approaches for diagnosing cancer earlier for patient sub-groups with common chronic 
diseases. Studies analyzing data from electronic health records could also be used for evaluating the 
effects of treatments for chronic conditions on timely cancer diagnosis at population level, expanding 
the currently limited evidence 10,86. 
Qualitative studies, including both patients and healthcare providers, could offer a deeper 
understanding of psychological factors influencing help-seeking and diagnostic decision-making in 
complex clinical situations. Multidisciplinary research, involving cognitive psychologists, could provide 
insights into the role of cognitive mechanisms or situational awareness, in influencing decision-
making in such circumstances. 
Patients’ and doctors’ tolerance of uncertainty can also influence diagnostic decision-making158; this 
is especially relevant for patients with multi-morbidity and poor overall health status and when 
chronic diseases (for example, cardiac conditions) increase the risk associated with invasive 
investigations. Considerations on the overall prognosis and life expectancy159,160, in relation to pre-
existing chronic conditions (which might include history of cancer) can play an important role in 
influencing diagnostic decisions. Patient's preferences when considering trade-offs between risks and 
benefits that may result from investigations become particularly important in such situations and a 
better understanding of the role of shared decision-making for patients with multi-morbidity is 
needed157,161.  
Finally, tailored risk-assessment tools need to be developed that take chronic morbidities and their 
treatments into account, in order to support clinicians in the decision-making process when 
evaluating the possibility of cancer in patients with multi-morbidities. Currently available tools are 
based on generic algorithms1, but more sophisticated approaches might take advantage of artificial 
intelligence. 
 
Conclusions 
Chronic diseases have multiple and sometimes contrasting effects on the timeliness of cancer 
diagnosis, acting through various mechanisms and affecting different aspects of the diagnostic 
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process. By evaluating disease-specific effects on participation in cancer screening, help-seeking for 
potential cancer symptoms and use of investigations, interventions can be identified to lower the risk 
of diagnosis of cancer at an advanced stage or through emergency presentation in the growing 
number of individuals with chronic diseases. Interventions could include the development of tailored 
diagnostic approaches encompassing risk-assessment tools and clinical guidelines targeting specific 
symptom-morbidity pairs, appropriate time and resource allocation in primary care for patients with 
complex needs (including the availability of specialist nurses) and greater integration of diagnostic 
services between primary and secondary care to optimise the management of multi-morbid patients 
and expedite cancer diagnosis. 
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Figure 1: Overview of studies providing evidence on the role of chronic diseases in influencing the diagnosis of cancer (studies providing quantitative evidence are shown here) 
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Figure 2: Mechanisms through which chronic diseases can influence the timely diagnosis of cancer along the diagnostic pathway 
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